Oxidative and antioxidative status after anthracyclinebased chemotherapy in breast cancer patients.
OBJECTIVE
The present study was undertaken to evaluate the effects of adjuvant anthracycline-based chemotherapy on thiobarbituric acid reactive substances (TBARS) and superoxide dismutase (SOD) levels in patients with breast cancer who had undergone surgery.


METHODS
Body mass index (BMI), serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), serum TBARS and SOD values were assessed in 30 patients with stage III breast cancer receiving adjuvant anthracycline- based chemotherapy.


RESULTS
Anthracycline-based chemotherapy had no effect on BMI, blood pressure and lipid profile. A significant elevation was noted in TBARS (5.5±0.6 vs 5.9±0.9 μmol/L; p=0.038) and a significant reduction to baseline values in SOD levels (226.5±61.0 vs 203.1±48.3 U/mL; p=0.03) in patients following 6 cycles of adjuvant chemotherapy.


CONCLUSIONS
The TBARS levels increased, whereas the SOD levels descreased after anthracycline-based chemotherapy. We suggest that oxidative stress is not always detrimental, as it can be beneficial in cancer treatment.
Department of Medical Oncology, Bozyaka Research and Training Hospital, Izmir, Turkey.
A
A
Alacacioglu
L
L
Kebapcilar
B
B
Onder Pamuk
G
G
Sop
C
C
Kucukiravul
G
G
Bozkaya
A
A
Yuksel
I
I
Alacacioglu
I
I
Sari
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018384:Oxidative Stress; D011379:Prognosis; D013482:Superoxide Dismutase / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D000975:Antioxidants; D014408:Biomarkers, Tumor; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D043823:Taxoids; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D002784:Cholesterol; D013482:Superoxide Dismutase